Results 171 to 180 of about 589,499 (392)
NeuroImage: Clinical, 2017 We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls.
Marios Politis +4 more
doaj
Dopamine modulation via memristive schematic [PDF]
arXiv, 2017 In this technical report we present novel results of the dopamine neuromodulation inspired modulation of a polyaniline (PANI) memristive device excitatory learning STDP. Results presented in this work are of two experiments setup computer simulation and physical prototype experiments.
arxiv
Endocannabinoid Involvement in Impulsivity and Decision-making [PDF]
, 2014 Problem gambling is a widespread phenomenon with a prevalence estimate of 2.3% globally (Williams, Volberg, & Stevens, 2012). Although little is known about the neurochemistry underlying this pathological behaviour, evidence suggests that dysregulation ...
Norris, Christopher P
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is a well‐established treatment for Parkinson's Disease (PD). However, the long‐term trajectory of Quality of Life (QoL) following STN‐DBS remains underexplored. Objectives We aimed to conduct a systematic review and meta‐analysis to assess QoL trends up to five years after
Luis Otávio Nogueira +11 more
wiley +1 more source
Journal of Clinical Endocrinology and Metabolism, 2010 CONTEXT Dopamine agonists are the treatment of choice for prolactinomas and symptomatic idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration is not clear in all details.
O. Dekkers +5 more
semanticscholar +1 more source
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Movement Disorders Clinical Practice, EarlyView.Abstract Background The gut‐brain axis, i.e. the bidirectional communication system between the gut and the brain, has become of central importance in Parkinson disease (PD) research over the past 20 years. Aims We aimed to describe the milestones of the gut‐brain axis research in PD and the development of theories proposing the involvement of the ...
Elisa Menozzi +2 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Restless Legs Syndrome (RLS) is a neurological disorder reported to be associated with impulsivity and impairments in interoception and emotional regulation. However, limited research has explored the combined influence of RLS severity, psychological factors, and chronotype on impulsive decision‐making and risk‐taking behavior in ...
Giacomo Carollo +5 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background The magnitude and factors associated with levodopa equivalent daily dose (LEDD) reduction in deep brain stimulation (DBS) of the globus pallidus interna (GPi) for Parkinson's Disease (PD) remain unclear. Objective To investigate LEDD reduction in GPi DBS and its correlation with anatomical/clinical characteristics.
Daniel G. Di Luca +7 more
wiley +1 more source
Agonist-Antagonist Pouch Motors: Bidirectional Soft Actuators Enhanced by Thermally Responsive Peltier Elements [PDF]
In this study, we introduce a novel Mylar-based pouch motor design that leverages the reversible actuation capabilities of Peltier junctions to enable agonist-antagonist muscle mimicry in soft robotics. Addressing the limitations of traditional silicone-based materials, such as leakage and phase-change fluid degradation, our pouch motors filled with ...
arxiv +1 more source
Evidence of Involvement of the Calcitonin Gene‐Related Peptide in Restless Legs Syndrome
Movement Disorders, EarlyView.Abstract Background Restless legs syndrome (RLS) is a common sensory‐motor disorder characterized by an urge to move the legs, often with unpleasant sensations, particularly during rest. Current treatments include iron supplementation, dopamine agonists, and opioids, but new therapeutic approaches are needed.
Maria P. Mogavero +8 more
wiley +1 more source